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Quick guide
Huntington’s disease
Also known as¼Huntington’s
chorea. The disease was named after
a young physician, George
Huntington, who in 1872 described
the spasmodic and uncoordinated
limb movement (chorea) afflicting a
handful of families of English
descent living in a region of Long
Island, New York. He had first
encountered these patients when he
was just 8 years old, accompanying
his father and grandfather on medical
rounds. For more than a century, the
disease has also erroneously been
referred to as ‘Huntingdon’s disease’.
What are the symptoms? The disease
is characterized by involuntary
movements, severe emotional
disturbance and cognitive decline. It
usually strikes in mid-adulthood and
progresses inexorably until death
occurs ten to twenty years later. The
disease, which affects about 1 in
10,000 people, is a dominantly
inherited trait.
Most famous case¼Woody Guthrie,
the father of American folk music,
who died of Huntington’s disease in
1967, at the age of 55. His son Arlo,
50, still shows no signs of the disease
and says “I’m living on free time.”
Most likely to be mentioned by¼
Nancy Wexler, a remarkable woman
whose mother died of the disease
and left Nancy and her sister with a
50:50 chance of developing it. Wexler
collected hundreds of blood samples
from the isolated inhabitants of Lake
Maracaibo in Venezuela — who
included scores of people affected
with Huntington’s disease — in the
hope they would somehow provide
the key to understanding it. As
President of the Hereditary Disease
Foundation (www.hdfoundation.org),
Wexler raises millions of dollars
for research.
Has the gene been mapped? With
the realization in the early 1980s
that inherited disease genes could
be mapped in large families,
Wexler’s Venezuelan samples
became a precious commodity. In
1983, James Gusella started linkage
studies with a random collection of
polymorphic markers on different
chromosomes. Incredibly, one of the
first dozen tested, called G8, from
chromosome 4, tracked with the
disease gene.
A short step to isolating the gene, then?
No. For the next decade, research
teams struggled to narrow the gap
between G8 and the Huntington’s
disease gene and to resolve
confusing data that prevented them
from pinpointing its precise location.
Who found the gene? A consortium of
almost 60 researchers, including
Gusella and Wexler, from six teams
working in Boston, London, Cardiff,
Michigan and California finally
identified the disease gene in 1993.
The lab name for the gene was
‘IT15’, for ‘interesting transcript 15’;
the protein was subsequently
dubbed ‘huntingtin’.
What causes the disease? In common
with genes involved in a number of
neurodegenerative diseases, the
Huntington’s disease gene contains a
triplet repeat sequence (CAG) that
encodes a run of glutamine residues
in the corresponding protein.
Healthy people have about 35 CAG
repeats in this gene but expansions
above this limit, sometimes to more
than 100, are invariably associated
with the disease. In general, the
longer the repeat, the earlier the age
of onset.
What is known about huntingtin? Not
much, other than that it is a large
protein (about 350 kDa), widely
expressed and essential for mouse
embryonic development. The
recent identification of proteins that
interact with huntingtin specifically
and in a glutamine-dependent
manner should shed some light on
this. What is clear is that the
increased run of glutamines causes
the mutant huntingtin protein to
form aggregates in and around the
nucleus in certain neurons. The
pathological significance of this is
borne out by similar observations in
other triplet repeat diseases,
including spinocerebellar ataxia.
Is any of the research looking
promising? The transgenic mouse
models that have recently been
developed should begin to pay
dividends. On the clinical front,
there is a trial under way in the US
of two drugs, Remacemide and
Coenzyme Q10, which may be able
to slow the pace of nerve damage.
Inhibitors of transglutaminases and
apoptosis could also prove effective
therapeutics down the line.
Meanwhile, what hope is there if you
carry the mutant gene? Nancy
Wexler summarized the profound
ethical dilemmas facing people who
learn they carry the gene for a fatal
disease with no immediate prospect
for a cure in the words of Tiresias,
who warned Oedipus: “It is but
sorrow to be wise when wisdom
profits not.”
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